Sign in to fuzzto save your conversations, follow your research and come back anytime.

Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs has four manufacturing facilities in Visakhapatnam, Andhra Pradesh, producing APIs, ingredients, and Finished Dosage Formulations (FDFs). The company serves global pharmaceutical markets, particularly in Sub-Saharan Africa, South-East Asia, and Latin America. Laurus Labs also offers contract development and manufacturing services, and produces specialty ingredients for the nutraceutical and cosmeceutical sectors. The company has expanded its operations through acquisitions, partnerships, and investments in new facilities and capabilities.
Company insights, generated from the most recent coverage.
Inclusion driven by strong free-float market cap and liquidity, benefiting from global pharmaceutical supply chain diversification trends.
Estimated $598 million passive inflow from MSCI inclusion creates inelastic demand pressure on Aug 31.
Large inflow relative to daily volume may cause price dislocation during closing auction session.
The Quarter story
The two most recent quarterly results, compared side-by-side.
Laurus Labs posts robust revenue growth and margin expansion, fueled by a CDMO surge, though ARV sales show weakness.
Consolidated revenue grows from ₹1,570 Cr in Q1 FY26 to ₹2,026 Cr in Q1 FY27.
ARV revenue declines from ₹744 Cr in Q3 FY26 to ₹669 Cr in Q1 FY27.
EBITDA margin expands from 24.8% in Q1 FY26 to 31.8% in Q1 FY27.
R&D spend increases from ₹68 Cr in Q1 FY26 to ₹118 Cr in Q1 FY27.
CDMO revenue surges from ₹522 Cr in Q1 FY26 to ₹870 Cr in Q1 FY27.
Bio revenue drops from ₹65 Cr in Q4 FY26 to ₹35 Cr in Q1 FY27.
Net profit rises from ₹163 Cr in Q1 FY26 to ₹368 Cr in Q1 FY27.